2nd Fc Receptor & IgG Targeted Therapies Summit
Evvnt Promotion / evvnt
Archive
26.04.2022 - 28.04.2022 Hilton Boston Back Bay, 40 Dalton Street, 02115 Boston, USA
Time: 9:00 AM - 4:00 PM
Conference themes
FcRn, Fcγ, and IgG studies have been propelled by drug developers recently after Argenx’s potential FDA’s approval of first-in-class FcRn antagonist efgartigimod, AstraZeneca-Alexion’s $39 billion deal, and positive clinical updates from UCB’s Rozanolixizumab. Successful modulation of the Fc pathways and optimized IgG antibodies have proven clinical utility and demonstrate significant therapeutic potential with more players poised to bring their candidates through clinic.
FcRn, Fcγ, and IgG studies have been propelled by drug developers recently after Argenx’s potential FDA’s approval of first-in-class FcRn antagonist efgartigimod, AstraZeneca-Alexion’s $39 billion deal, and positive clinical updates from UCB’s Rozanolixizumab. Successful modulation of the Fc pathways and optimized IgG antibodies have proven clinical utility and demonstrate significant therapeutic potential with more players poised to bring their candidates through clinic.
Professional congress organizer (PCO)
Hanson Wade
Hanson Wade
Enquiries and Registration:
https://go.evvnt.com/972245-1?pid=4832
Ms. Erin Thomas
General Medicine
Languages
English
English
Congress fees
Conference + 2 Workshops - Pharma Biotech USD 3897.00, Conference Only - Pharma Biotech USD 2999.00, Conference + 2 Workshops - Service provider USD 4697.00, Conference Only - Service provider USD 3599.00
Conference + 2 Workshops - Pharma Biotech USD 3897.00, Conference Only - Pharma Biotech USD 2999.00, Conference + 2 Workshops - Service provider USD 4697.00, Conference Only - Service provider USD 3599.00
Participants expected
1000
1000
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International promotes access to education and training for all regardless of social, geographic and national borders."
